2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Combination Therapy, Therapy Sequence, Biological Therapies, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, CML, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

5070 Phase II study of pedi-crib: Mini-hyper-CVD with condensed rituximab, inotuzumab ozogamicin and blinatumomab (cRIB) for relapsed therapy for pediatric patients with B-cell lineage acute lymphocytic leukemia

David McCall, MD, Amber Gibson, DO2, Nicholas Short, MD3, Samanta Catueno, MD4, Miriam B. Garcia, DO5, Cesar Nunez, MD6, Michael Roth, MD7, Guillermo Garcia-Manero, MD8, Elias Jabbour, MD9, Branko Cuglievan, MD10
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
10 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Background: Outcomes for children with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) remain limited by the toxicity and incomplete efficacy of conventional re-induction strategies. Standard approaches are associated with significant infectious complications, treatment-related mortality, and persistent measurable residual disease (MRD), which may delay potentially curative cellular therapies. To address these challenges, we initiated a phase II study (NCT05645718) evaluating a reduced-intensity chemoimmunotherapy regimen consisting of mini-hyper-CVD, rituximab, inotuzumab ozogamicin (InO), and blinatumomab (pedi-cRIB). This approach combines targeted immunotherapy with lower-intensity chemotherapy during hematologic recovery to improve remission depth while minimizing toxicity.

Methods: This single-center, open-label phase II trial evaluates a reduced-intensity chemoimmunotherapy platform for patients aged 1-25 years with relapsed or refractory B-ALL. Treatment consists of six 28-day cycles of alternating mini-hyper-CVD (A/B) chemotherapy with overlapping administration of rituximab, InO, and blinatumomab. Eligibility requires expression of CD19 and CD22; CD20 expression is not required. Patients receive 3 doses of InO during cycle 1 (1.2 mg/m2) followed by twice monthly dosing (0.6 mg/m2) in subsequent cycles. The first 4 cycles contained InO and Rituximab (if CD20+). Blinatumomab was started on day 14 of cycle 1 and day 4 on each of the subsequent 5 cycles. Patients not proceeding to allogeneic hematopoietic stem cell transplantation (HSCT) received 12 POMP maintenance cycles with scheduled blinatumomab every third cycle following the 6 chemoimmunotherapy cycles. The primary endpoint is complete remission (CR); secondary endpoints include MRD negativity, event-free survival (EFS), and overall survival (OS).
 
Results: As of July 2026, seven pediatric and young adult patients with relapsed (n=5) or primary refractory (n=2) B-ALL were enrolled, treated, and evaluable for response. The median age was 13 years (range, 5-20), and four patients (57%) had received prior CD19-directed therapy. High-risk disease features included complex karyotype (n=3), Philadelphia-like ALL (n=4), including EPOR rearrangements (n=2), Philadelphia chromosome-positive ALL (n=1), PAX5 alterations (n=2), and one patient with MYC-rearranged Burkitt-like CNS lymphoma that evolved to leukemia.
 
All seven patients achieved bone marrow CR following cycle 1. Six patients (86%) achieved multiparameter flow cytometry (MFC)-MRD negativity by the end of cycle 1, and the remaining patient became MRD-negative by day 15 (while on blinatumomab) of cycle 2. Five (71%) patients achieved next-generation sequencing (NGS)-MRD negativity at the end of cycle 1. Six (86%) patients achieved NGS-MRD negativity after cycle 2, before consolidative therapy. One patient had persistent, rare blastoid cells confined to the CNS despite MRD-negative and NGS-negative marrow assessments; CNS disease completely resolved by the end of cycle 2. Overall, six of seven patients achieved both MFC- and NGS-MRD negativity before proceeding to HSCT (n=4) or CD19-directed CAR T-cell therapy (n=2). Median cumulative dose of InO prior to SCT was 1.2mg/m2 and there have been no cases of veno-occlusive disease surrounding HSCT. One patient who presented as a late relapse did not get a HSCT, remains in remission and continues protocol-directed maintenance therapy.
 
At a median follow-up of 12 months (range, 2-32), no patient has relapsed. One patient died from sepsis approximately one month following HSCT; no treatment-related deaths were observed. The regimen was well tolerated. No patients developed febrile neutropenia or grade ≥3 infections during cycle 1. The most common grade 3-4 adverse events were hematologic and included neutropenia, leukopenia, and thrombocytopenia.

Conclusions: This interim analysis demonstrates encouraging efficacy and tolerability of pedi-cRIB in a high-risk pediatric and young adult B-ALL population, including patients previously exposed to CD19-directed therapy. Deep remissions were achieved in all treated patients, with high rates of both MFC- and NGS-MRD negativity and no disease relapses observed to date. Ongoing enrollment and planned multicenter expansion will further define the safety and efficacy of this approach.
David McCall, MD: No relevant conflicts of interest to declare.